Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers

Histopathology

Volumn 46, Issue 6, 2005, Pages 622-634

  Llombart, Beatriz ^a,c   Monteagudo, C ^a   Lopez Guerrero J A ^b   Carda, C ^a   Jorda, E ^c   Sanmartin O ^b   Almenar, S ^b   Molina, I ^c   Martin J M ^c   Llombart Bosch, A ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

C kit; CD99; CK20; Cutaneous neuroendocrine carcinoma; Fli 1; K167; Merkel cell carcinoma; Prognostic factors; TTF 1

Indexed keywords

CD99 ANTIGEN; CELL PROTEIN; CHROMOGRANIN A; CYTOKERATIN 20; KI 67 ANTIGEN; PROTEIN P53; STEM CELL FACTOR; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL SIZE; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; MERKEL CELL TUMOR; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARCINOMA, MERKEL CELL; CELL ADHESION MOLECULES; CHROMOGRANIN A; CHROMOGRANINS; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; KERATIN-20; KI-67 ANTIGEN; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL ANALYSIS; SYNAPTOPHYSIN; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20644455344     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02158.x     Document Type: Article

References (49)

1. Toker C. Trabecular carcinoma of the skin. Arch. Dermatol. 1972; 105; 107-110.
2. Tang CK. Toker C. Trabecular carcinoma of the skin: further clinicopathologic and ultrastructural study. Mt Sinai J. Med. 1979; 46; 516-523.
3. Benessahraoui M, Dalstein V, Lorchel F et al. [Merkel cell carcinoma: descriptive study of 24 cases (1993-2001)]. Rev. Med. Interne 2003; 24; 560-568.
4. Gould VE, Dardi LE, Memoli VA, Johannessen JV. Neuroendocrine carcinomas of the skin: light microscopic, ultrastructural, and immunohistochemical analysis. Ultrastruct. Pathol. 1980; 1; 499-509.
5. Koljonen V, Bohling T, Granhroth G, Tukiainen E. Merkel cell carcinoma: a clinicopathological study of 34 patients. Eur. J. Surg. Oncol. 2003; 29; 607-610.
6. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J. Am. Acad. Dermatol. 2003; 49; 832-841.
7. Mott RT, Smoller BR, Morgan MB. Merkel cell carcinoma: a clinicoputhologic study with prognostic implications. J. Cutan. Pathol 2004; 31; 217-223.
8. Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP, Graham JH. Merkel cell carcinoma: analysis of clinical, histologie, and immunohistologic features of 132 cases with relation to survival. J. Am. Acad. Dermatol 1997; 37; 734-739.
9. Carson HJ, Reddy V, Taxy JB. Proliferation markers and prognosis in Merkel cell carcinoma. J. Cutan. Pathol. 1998; 25; 16-19.
10. Argenyi ZB. Neural and neuroendocrine tumors. In Barnhill RL ed. Textbook of dermatopathology. New York: McGraw-Hill, 1998; 747-762.
11. Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am. J. Clin. Pathol. 2002; 118; 504-511.
12. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 1981; 29; 577-580.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53; 457-481.
14. Peto R, Peto P. Asymptomatically efficient rank invariant test procedures. J. Roy. Stat. 1987; 135; 185-206.
15. Cox D. Regression models and life tables. J. R. Stat. Soc. 1972; 34; 187-220.
16. Ott MJ, Tanabe KK, Gadd MA et al. Multimodality management of Merkel cell carcinoma. Arch. Surg. 1999; 134; 388-392: discussion 392-383.
17. Hitchcock CL, Bland KI, Laney RG 3rd, Franzini D, Harris B, Copeland EM 3rd. Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann. Surg. 1988; 207; 201-207.
18. Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope 1992; 102; 244-249.
19. Shaw JH, Rumball E. Merkel cell tumour: clinical behaviour and treatment. Br. J. Surg. 1991; 78; 138-142.
20. Akhtar S, Oza KK, Wright J. Merkel cell carcinoma: report of 10 cases and review of the literature. J. Am. Acad. Dermatol 2000; 43; 755-767.
21. Boyle F, Pendlebury S, Bell D. Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1995; 31; 315-323.
22. Ziprin P, Smith S, Salerno G, Rosin RD. Two cases of merkel cell tumour arising in patients with chronic lymphocytic leukaemia. Br. J. Dermatol 2000; 142; 525-528.
23. Urbatsch ASWJ, Urist MM, Sturdivant R. Merkel cell carcinoma occurring in renal transplant patients. J. Am. Acad. Dermatol. 1999; 41; 289-291.
24. Veness MJ. Aggressive skin cancers in a cardiac transplant recipient. Australas. Radiol. 1997; 41; 363-366.
25. Samarendra P, Berkowitz L, Kumari S, Alexis R. Primary nodal neuroendocrine (Merkel cell) tumor in a patient with HIV infection. South Med. J. 2000; 93; 920-922.
26. Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C, Knapper WK. Merkel cell carcinoma. Prognosis and management. Arch. Surg. 1991; 126; 1514-1519.
27. Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. J. Clin. Oncol. 2002; 20; 588-598.
28. Allen PJ, Zhang ZF, Coit DG. Surgical management of Merkel cell carcinoma. Ann. Surg. 1999; 229; 97-105.
29. Fenig E, Brenner B, Katz A, Rakovsky E, Hana MB, Sulkes A. The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer 1997; 80; 881-885.
30. Gomez LG, DiMaio S, Silva EG, Mackay B. Association between neuroendocrine (Merkel cell) carcinoma and squamous carcinoma of the skin. Am. J. Surg. Pathol. 1983; 7; 171-177.
31. Cerroni L, Kerl H. Primary cutaneous neuroendocrine (Merkel cell) carcinoma in association with squamous- and basal-cell carcinoma. Am. J. Dermatopathol. 1997; 19; 610-613.
32. Fernandez-Figueras MT, Puig L, Gilaberte M et al. Merkel cell (primary neuroendocrine) carcinoma of the skin with nodal metastasis showing rhabdomyosarcomatous differentiation. J. Cutan. Pathol 2002; 29; 619-622.
33. Cooper L, Debono R, Alsanjari N, Al-Nafussi A. Merkel cell tumour with leiomyosarcomatous differentiation. Histopathology 2000; 36; 540-543.
34. Rosso R, Paulli M, Carnevali L. Neuroendocrine carcinoma of the skin with lymphoepithelioma-like features. Am. J. Dermatopathol 1998; 20; 483-486.
35. Boutilier R, Desormeau L, Cragg F, Roberts P, Walsh N. Merkel cell carcinoma: squamous and atypical fibroxanthoma-like differentiation in successive local tumor recurrences. Am. J. Dermatopathol. 2001; 23; 46-49.
36. Ladanyi A. [Function and prognostic significance of immune cells infiltrating human tumors]. Magy. Onkol 2004; 48; 49-56.
37. Kennedy MM, Blessing K, King G, Kerr KM. Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am. J. Dermatopathol. 1996; 18; 273-277.
38. Feinmesser M, Halpern M, Fenig E et al. Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome? Hum. Pathol 1999; 30; 1367-1372.
39. Chan JK, Suster S, Wenig BM, Tsang WY, Chan JB, Lau AL. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am. J. Surg. Pathol. 1997; 21; 226-234.
40. Scott MP, Helm KF. Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma. Am. J. Dermatopathol 1999; 21; 16-20.
41. Byrd-Gloster AL, Khoor A, Glass LF et al. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum. Pathol 2000; 31; 58-62.
42. Hanly AJ, Elgart GW, Jorda M, Smith J, Nadji M. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinoma from small cell carcinoma of lung. J. Cutan. Pathol 2000; 27; 118-120.
43. Leech SN, Kolar AJ, Barrett PD, Sinclair SA, Leonard N. Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1. J. Clin. Pathol 2001; 54; 727-729.
44. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am. J. Surg. Pathol 2000; 24; 1217-1223.
45. Rossi S, Orvieto E, Furlanetto A, Laurino L, Ninfo V, Dei Tos AP. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod. Pathol 2004; 17; 547-552.
46. Su LD, Fullen DR, Lowe L, Uherova P, Schnitzer B, Valdez R. CD117 (KIT receptor) expression in Merkel cell carcinoma. Am. J. Dermatopathol. 2002; 24; 289-293.
47. Strong S, Shalders K, Carr R, Snead DR. KIT receptor (CD117) expression in Merkel cell carcinoma. Br. J. Dermatol. 2004; 150; 384-385.
48. Demetri GD. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol. Oncol. Clin. North. Am. 2002; 16; 1115-1124.
49. Bono P, Krause A, von Mehren M et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 2004; 103; 2929-2935.